Christian Todd Nichols, the SVP of $ALKS, sold 664 shares of the company on 08-17-2026 for an estimated $32,969. We received data on the trade from a recent SEC filing. This was a sale of approximately 0.6% of their shares of this class of stock. Following this trade, they now own 102,193 shares of this class of $ALKS stock.
$ALKS Insider Trading Activity
$ALKS insiders have traded $ALKS stock on the open market 21 times in the past 6 months. Of those trades, 0 have been purchases and 21 have been sales.
Here’s a breakdown of recent trading of $ALKS stock by insiders over the last 6 months:
- NANCY LYNN MD SNYDERMAN sold 44,472 shares for an estimated $2,239,076
- CRAIG C. HOPKINSON (EVP R&D, Chief Medical Officer) has made 0 purchases and 7 sales selling 54,000 shares for an estimated $2,163,533.
- SAMUEL JOSEPH PARISI (VP, Finance (Interim PAO)) has made 0 purchases and 2 sales selling 23,107 shares for an estimated $888,815.
- DAVID JOSEPH GAFFIN (EVP, CLO, Alkermes, Inc.) has made 0 purchases and 7 sales selling 14,238 shares for an estimated $554,224.
- CHRISTIAN TODD NICHOLS (SVP, Chief Commercial Officer) has made 0 purchases and 3 sales selling 13,576 shares for an estimated $552,936.
- CHRISTOPHER I WRIGHT sold 2,000 shares for an estimated $90,200
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
$ALKS Hedge Fund Activity
We have seen 231 institutional investors add shares of $ALKS stock to their portfolio, and 215 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- SIXTH STREET PARTNERS MANAGEMENT COMPANY, L.P. added 2,335,117 shares (+inf%) to their portfolio in Q2 2026, for an estimated $122,348,455
- AMERICAN CENTURY COMPANIES INC removed 2,117,864 shares (-34.9%) from their portfolio in Q2 2026, for an estimated $110,965,484
- PRICE T ROWE ASSOCIATES INC /MD/ added 2,072,752 shares (+44.4%) to their portfolio in Q2 2026, for an estimated $108,601,841
- ARROWSTREET CAPITAL, LIMITED PARTNERSHIP removed 1,450,841 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $51,301,737
- ADAGE CAPITAL PARTNERS GP, L.L.C. added 1,368,000 shares (+inf%) to their portfolio in Q2 2026, for an estimated $71,676,360
- BAIN CAPITAL LIFE SCIENCES INVESTORS, LLC added 1,327,938 shares (+217.7%) to their portfolio in Q2 2026, for an estimated $69,577,311
- HOLOCENE ADVISORS, LP added 1,284,146 shares (+55.4%) to their portfolio in Q2 2026, for an estimated $67,282,829
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
$ALKS Analyst Ratings
Wall Street analysts have issued reports on $ALKS in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- UBS issued a "Buy" rating on 05/06/2026
To track analyst ratings and price targets for $ALKS, check out Quiver Quantitative's $ALKS forecast page.
$ALKS Price Targets
Multiple analysts have issued price targets for $ALKS recently. We have seen 10 analysts offer price targets for $ALKS in the last 6 months, with a median target of $49.0.
Here are some recent targets:
- Uy Ear from Mizuho set a target price of $65.0 on 07/02/2026
- Benjamin Burnett from Wells Fargo set a target price of $65.0 on 06/29/2026
- Jason Gerberry from B of A Securities set a target price of $38.0 on 06/29/2026
- Ami Fadia from Needham set a target price of $61.0 on 06/24/2026
- Joseph Thome from TD Cowen set a target price of $50.0 on 06/22/2026
- Leonid Timashev from RBC Capital set a target price of $56.0 on 06/09/2026
- Joel Beatty from Baird set a target price of $48.0 on 05/13/2026
This article is not financial advice. See Quiver Quantitative's disclaimers for more information.
